Type 2 Diabetes Mellitus and Heart Failure: A Position Statement from the Heart Failure Association of the European Society of Cardiology
Population
Patients with coexisting type 2 diabetes mellitus (T2DM) and heart failure (HFrEF or HFpEF)
Design
Guideline
Authors
Discussion
Loading...
Member takes
Implication
Recommend SGLT2 inhibitors and avoid thiazolidinediones in T2DM with or at HF risk; extends RCT data into clinical guidance.
Structured PICO
P
Population
Patients with coexisting type 2 diabetes mellitus (T2DM) and heart failure (HFrEF or HFpEF)
I
Intervention
Heart failure therapies and T2DM treatments (including metformin, SGLT2 inhibitors, GLP-1 receptor agonists, DPP4 inhibitors, and thiazolidinediones)
This position statement outlines the management of patients with concurrent T2DM and heart failure, emphasizing the safety and efficacy of standard HF therapies and the benefit of SGLT2 inhibitors.
Cite This Study
Seferović et al. (2018) conducted a review in Type 2 Diabetes Mellitus and Heart Failure. A position statement highlighting that SGLT2 inhibitors reduce heart failure hospitalization in patients with or at risk of cardiovascular disease, while thiazolidinediones are contraindicated.